ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2020.05.15 Structural Analysis of Small Molecule Inhibitors Binding to TMPRSS2.pdf (935.67 kB)
0/0

Structural Analysis of Experimental Drugs Binding to the COVID-19 Target TMPRSS2

preprint
submitted on 15.05.2020 and posted on 18.05.2020 by David Huggins

The emergence of SARS-CoV-2 has prompted a worldwide health emergency. There is an urgent need for therapeutics, both through the repurposing of approved drugs and the development of new treatments. In addition to the viral drug targets, a number of human drug targets have been suggested. In theory, targeting human proteins should provide an advantage over targeting viral proteins in terms of drug resistance, which is commonly a problem in treating RNA viruses. This paper focuses on the human protein TMPRSS2, which supports coronavirus life cycles by cleaving viral spike proteins. The three-dimensional structure of TMPRSS2 is not known and so we have generated models of the TMPRSS2 in the apo state as well as in complex with a peptide substrate and putative inhibitors to aid future work. Importantly, many related human proteases have 80% or higher identity with TMPRSS2 in the S1-S1’ subsites, with plasminogen and urokinase-type plasminogen activator (uPA) having 95% identity. We highlight 376 approved, investigational or experimental drugs targeting S1A serine proteases that may inhibit TMPRSS2. Whilst the presence of a relatively uncommon lysine residue in the S2/S3 subsites means that many serine protease inhibitors may not inhibit TMPRSS2, this is likely to provide a handle for selective targeting. We discuss how experimental drugs targeting related serine proteases might be repurposed as TMPRSS2 inhibitors to treat coronaviruses.


History

Email Address of Submitting Author

dhuggins@tritdi.org

Institution

Tri-Institutional Therapeutics Discovery Institute

Country

United States

ORCID For Submitting Author

0000-0003-1579-2496

Declaration of Conflict of Interest

The authors declare no conflicts of interest

Exports

Logo branding

Exports